Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 3, 2012

View Archived Issues

Xention identifies novel ion channel blockers for atrial fibrillation

Seachaid Pharmaceuticals compounds active against Gram-positive bacteria

Opaxio receives FDA orphan drug designation

Coyote Pharmaceuticals plans clinical program with CNS-102

Encouraging phase III results for rFIXFc in hemophilia B

Pfizer discloses new antibacterial agents

Novel TRPM8 channel antagonists presented by Pfizer

PAC-14028 evaluated as a treatment for pruritus

The Vanderbilt University patents new mGlu5 receptor allosteric modulators

Czech scientists report novel dual PGE2 and NO production inhibitors

NuCana BioMed synthesizes new thymidylate synthase inhibitors

Phase IIb study of NBI-98854 in tardive dyskinesia commences

Eliglustat tartrate meets primary endpoint in phase III trial in Gaucher's disease

FDA panel recommends approval of Argus II Retinal Prosthesis System

Acacia Pharma reports results from phase IIa APD-403 study

IND cleared for Omeros' lead PDE10 candidate

NIAID grant awarded to AvidBiotics for antibacterial proteins

Diacomit approved in Japan for Dravet syndrome

Japanese approval granted for Buphenyl for urea cycle disorders

Delamanid can be administered with efavirenz

GTx sells Fareston

SBIR grant supports Colby Pharmaceutical's work in prostate cancer

ArQule and Daiichi Sankyo discontinue phase III MARQUEE trial

NDA submitted for vortioxetine for major depressive disorder

Janssen licenses rights to Astellas' oral JAK inhibitor

U.S. government awards GeoVax a grant for its HIV vaccine program

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...